Cargando…
Baseline procalcitonin as a predictor of bacterial infection and clinical outcomes in COVID-19: A case-control study
PURPOSE: Coronavirus disease-2019 (COVID-19) is associated with a wide spectrum of clinical symptoms including acute respiratory failure. Biomarkers that can predict outcomes in patients with COVID-19 can assist with patient management. The aim of this study is to evaluate whether procalcitonin (PCT...
Autores principales: | Atallah, Natalie J., Warren, Hailey M., Roberts, Matthew B., Elshaboury, Ramy H., Bidell, Monique R., Gandhi, Ronak G., Adamsick, Meagan, Ibrahim, Maryam K., Sood, Rupali, Bou Zein Eddine, Savo, Cobler-Lichter, Matthew J., Alexander, Natalie J., Timmer, Kyle D., Atallah, Christine J., Viens, Adam L., Panossian, Vahe S., Scherer, Allison K., Proctor, Teddie, Smartt, Sherrie, Letourneau, Alyssa R., Paras, Molly L., Johannes, Sascha, Wiemer, Jan, Mansour, Michael K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758006/ https://www.ncbi.nlm.nih.gov/pubmed/35025929 http://dx.doi.org/10.1371/journal.pone.0262342 |
Ejemplares similares
-
Mid-regional Proadrenomedullin Biomarker Predicts Coronavirus Disease 2019 Clinical Outcomes: A US-Based Cohort Study
por: Atallah, Natalie J, et al.
Publicado: (2022) -
856. CT-proET-1 and sFlt-1 as Predictors of Clinical Outcomes in a COVID-19 US Cohort
por: Atallah, Johnny, et al.
Publicado: (2023) -
61. Evaluation of the Impact of a Micafungin Time-Out Protocol for Hospitalized Patients
por: Williams, Kelsey N, et al.
Publicado: (2020) -
Remdesivir use and outcomes during the FDA COVID-19 emergency use
authorization period
por: Elshaboury, Ramy H., et al.
Publicado: (2021) -
756. Impact of Infectious Diseases Pharmacists as Part of an Interdisciplinary OPAT Team Managing Vancomycin
por: Adamsick, Meagan L, et al.
Publicado: (2019)